Featured News

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The Celiac Disease Foundation is proud to continue our partnership with the Celiac Disease Center at Columbia University in presenting an annual free livestream international symposium, this year titled "Celiac Disease: On the Horizon". Registration open now.

For the first time ever, access for funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP) Peer Review Medical Research Program Listing.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

The risk of developing CAD in celiac patients was found to be higher for white males, and patients with celiac disease and CAD are more likely to have disorders such as high cholesterol, type 2 diabetes, and iron-deficiency anemia.  

Last week in Washington, D.C., the Celiac Disease Foundation and our allies secured two critical wins in our mission to drive policy change to improve the health of those living with celiac disease.

New research studying the association of celiac disease and inflammatory bowel disease (IBD) shows a strong relationship between the two conditions.

Curing Celiac: A Short Story, a new film by Hayley Repton, encourages patients to join the iCureCeliac® patient registry, the single best patient-centered resource for celiac disease researchers in the world.